Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Anthony J, Rodgers"'
Autor:
Edwin, DeJesus, Jürgen K, Rockstroh, Jeffrey L, Lennox, Michael S, Saag, Adriano, Lazzarin, Jing, Zhao, Hong, Wan, Anthony J, Rodgers, Monica L, Walker, Michael, Miller, Mark J, DiNubile, Bach-Yen, Nguyen, Hedy, Teppler, Randi, Leavitt, Peter, Sklar, D, Wright
Publikováno v:
HIV clinical trials. 13(4)
We compared 4 years of antiretroviral therapy with tenofovir/emtricitabine and either raltegravir or efavirenz from the ongoing STARTMRK study of treatment-naive HIV-infected patients. Through 192 weeks, raltegravir produced durable and consistent vi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e2be1b482aed6e9fbc603e475dc45ce
https://pubmed.ncbi.nlm.nih.gov/22849964
https://pubmed.ncbi.nlm.nih.gov/22849964
Autor:
Jeffrey L, Lennox, Edwin, Dejesus, Daniel S, Berger, Adriano, Lazzarin, Richard B, Pollard, Jose Valdez, Ramalho Madruga, Jing, Zhao, Hong, Wan, Christopher L, Gilbert, Hedy, Teppler, Anthony J, Rodgers, Richard J O, Barnard, Michael D, Miller, Mark J, Dinubile, Bach-Yen, Nguyen, Randi, Leavitt, Peter, Sklar, D, Wright
Publikováno v:
Journal of acquired immune deficiency syndromes (1999). 55(1)
BACKGROUND We analyzed the 96-week results in the overall population and in prespecified subgroups from the ongoing STARTMRK study of treatment-naive HIV-infected patients. METHODS Eligible patients with HIV-1 RNA (vRNA) levels >5000 copies per milli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::043accdc2ae85dfd7e0caa2e6d4cec71
https://pubmed.ncbi.nlm.nih.gov/20404738
https://pubmed.ncbi.nlm.nih.gov/20404738
Autor:
Joseph J, Eron, Benjamin, Young, David A, Cooper, Michael, Youle, Edwin, Dejesus, Jaime, Andrade-Villanueva, Cassy, Workman, Roberto, Zajdenverg, Gerd, Fätkenheuer, Daniel S, Berger, Princy N, Kumar, Anthony J, Rodgers, Melissa A, Shaughnessy, Monica L, Walker, Richard J O, Barnard, Michael D, Miller, Mark J, Dinubile, Bach-Yen, Nguyen, Randi, Leavitt, Xia, Xu, Peter, Sklar, D P, Wright
Publikováno v:
Lancet (London, England). 375(9712)
To reduce lipid abnormalities and other side-effects associated with antiretroviral regimens containing lopinavir-ritonavir, patients might want to switch one or more components of their regimen. We compared substitution of raltegravir for lopinavir-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d85b62239e2d532140dd22c3b391d97d
https://pubmed.ncbi.nlm.nih.gov/20074790
https://pubmed.ncbi.nlm.nih.gov/20074790
Autor:
Jeffrey L, Lennox, Edwin, DeJesus, Adriano, Lazzarin, Richard B, Pollard, Jose Valdez Ramalho, Madruga, Daniel S, Berger, Jing, Zhao, Xia, Xu, Angela, Williams-Diaz, Anthony J, Rodgers, Richard J O, Barnard, Michael D, Miller, Mark J, DiNubile, Bach-Yen, Nguyen, Randi, Leavitt, Peter, Sklar, D, Wright
Publikováno v:
Lancet (London, England). 374(9692)
Use of raltegravir with optimum background therapy is effective and well tolerated in treatment-experienced patients with multidrug-resistant HIV-1 infection. We compared the safety and efficacy of raltegravir with efavirenz as part of combination an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ae4f1f3f28798942baec19d39cae2dc
https://pubmed.ncbi.nlm.nih.gov/19647865
https://pubmed.ncbi.nlm.nih.gov/19647865
Autor:
Jacques E. Chelly, Carl W. Nissen, Anthony J. Rodgers, Steven S. Smugar, Andrew M. Tershakovec
Publikováno v:
Current Medical Research & Opinion; Jan2007, Vol. 23 Issue 1, p195-206, 12p